Cognate BioServices, a Memphis TN-based contract development and manufacturing organization in the global cellular therapies industry, closed on a round of growth capital from EW Healthcare Partners.
The amount of the deal was not disclosed.
Led by J. Kelly Ganjei, CEO, Cognate provides a broad range of commercialization services to regenerative medicine, cellular immunotherapy and advance cell therapy companies. The company provides a combination of custom services to companies across all points of clinical and commercial development specializing in mid to late stage clinical trials and supporting clients through product scale-up into commercial manufacturing.
Cognate, which has commercial scale manufacturing capacity in Memphis, Tennessee to support products for both the E.U. and the U.S., intends to use the funds to continue to expand its commercial expansion that started in 2015.